| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| 2528- | H2, | Local generation of hydrogen for enhanced photothermal therapy |
| - | in-vitro, | Var, | NA |
| 2529- | H2, | Guidelines for the selection of hydrogen gas inhalers based on hydrogen explosion accidents |
| - | Analysis, | Nor, | NA |
| 2530- | H2, | Improvement of psoriasis-associated arthritis and skin lesions by treatment with molecular hydrogen: A report of three cases |
| - | Case Report, | PSA, | NA |
| 3152- | H2, | VitC, | Rad, | Hydrogen and Vitamin C Combination Therapy: A Novel Method of Radioprotection |
| - | in-vitro, | Nor, | HUVECs | - | in-vivo, | NA, | NA |
| 1637- | HCA, | OLST, | Orlistat and Hydroxycitrate Ameliorate Colon Cancer in Rats: The Impact of Inflammatory Mediators |
| - | in-vivo, | Colon, | NA |
| 1589- | HCA, | ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism |
| - | Review, | NA, | NA |
| 1627- | HCA, | CRMs, | Sper, | Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance |
| - | Review, | Var, | NA |
| 1628- | HCA, | ALA, | effreydachmd.com/2016/05/alpha-lipoic-acid-anticancer-agent-burt-berkson-md/">Addition of Hydroxy Citrate improves effect of ALA |
| - | Review, | Var, | NA |
| 1629- | HCA, | Tam, | Hydroxycitric acid reverses tamoxifen resistance through inhibition of ATP citrate lyase |
| - | in-vitro, | BC, | MCF-7 |
| 1634- | HCA, | Hydroxycitrate: a potential new therapy for calcium urolithiasis |
| - | Human, | Nor, | NA |
| 1643- | HCAs, | Mechanisms involved in the anticancer effects of sinapic acid |
| - | Review, | Var, | NA |
| 1439- | HCQ, | Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine |
| - | in-vitro, | Melanoma, | NA | - | in-vitro, | CRC, | HCT116 |
| 2072- | HNK, | Honokiol Suppresses Cell Proliferation and Tumor Migration through ROS in Human Anaplastic Thyroid Cancer Cells |
| - | in-vitro, | Thyroid, | NA |
| 2073- | HNK, | Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo |
| - | in-vitro, | OS, | U2OS | - | in-vivo, | NA, | NA |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LoVo | - | in-vivo, | CRC, | HCT116 |
| 4522- | HNK, | MAG, | Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth |
| - | in-vitro, | HNSCC, | FaDu |
| 2872- | HNK, | Honokiol alleviated neurodegeneration by reducing oxidative stress and improving mitochondrial function in mutant SOD1 cellular and mouse models of amyotrophic lateral sclerosis |
| - | in-vivo, | ALS, | NA | - | NA, | Stroke, | NA | - | NA, | AD, | NA | - | NA, | Park, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2886- | HNK, | Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vivo, | NA, | NA |
| 2895- | HNK, | Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity |
| - | in-vitro, | Lung, | PC9 |
| 5054- | HPT, | Induction of Oxidative Stress by Hyperthermia and Enhancement of Hyperthermia-Induced Apoptosis by Oxidative Stress Modification |
| - | Review, | Var, | NA |
| 5051- | HPT, | doxoR, | Hyperthermia Enhances Doxorubicin Therapeutic Efficacy against A375 and MNT-1 Melanoma Cells |
| - | in-vitro, | Melanoma, | A375 |
| 4641- | HT, | Hydroxytyrosol induced ferroptosis through Nrf2 signaling pathway in colorectal cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 1925- | JG, | Redox regulation of mitochondrial functional activity by quinones |
| - | in-vitro, | NA, | NA |
| 1924- | JG, | Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway |
| - | in-vitro, | Lung, | A549 |
| 1922- | JG, | Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 1919- | JG, | The Anti-Glioma Effect of Juglone Derivatives through ROS Generation |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 5114- | JG, | Juglone, from Juglans mandshruica Maxim, inhibits growth and induces apoptosis in human leukemia cell HL-60 through a reactive oxygen species-dependent mechanism |
| - | in-vitro, | AML, | HL-60 |
| 5115- | JG, | Natural Products to Fight Cancer: A Focus on Juglans regia |
| - | Review, | Var, | NA |
| 4011- | K+, | Sodium and potassium intakes among US adults: NHANES 2003–2008 |
| - | Analysis, | NA, | NA |
| 4014- | K+, | The effects of boiling and leaching on the content of potassium and other minerals in potatoes |
| - | Analysis, | NA, | NA |
| 2390- | KaempF, | Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis |
| - | in-vitro, | CRC, | HCT8 |
| 860- | Lae, | Amygdalin as a Promising Anticancer Agent: Molecular Mechanisms and Future Perspectives for the Development of New Nanoformulations for Its Delivery |
| - | Review, | NA, | NA |
| 2351- | lamb, | Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 1790- | LEC, | DHA, | Dietary Crude Lecithin Increases Systemic Availability of Dietary Docosahexaenoic Acid with Combined Intake in Rats |
| - | in-vivo, | Nor, | NA |
| 1791- | LEC, | Vegetable lecithins: A review of their compositional diversity, impact on lipid metabolism and potential in cardiometabolic disease prevention |
| - | Review, | Nor, | NA |
| 1795- | LEC, | Chit, | Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene |
| - | in-vivo, | Nor, | NA |
| 4292- | LT, | Luteolin for neurodegenerative diseases: a review |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | MS, | NA | - | Review, | Stroke, | NA |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | PC, | Bxpc-3 |
| 2907- | LT, | Protective effect of luteolin against oxidative stress‑mediated cell injury via enhancing antioxidant systems |
| - | in-vitro, | Nor, | NA |
| 2910- | LT, | FA, | Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 2904- | LT, | Luteolin from Purple Perilla mitigates ROS insult particularly in primary neurons |
| - | in-vitro, | Park, | SK-N-SH | - | in-vitro, | AD, | NA |
| 2903- | LT, | Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 2920- | LT, | Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 2919- | LT, | Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence |
| - | Review, | Var, | NA |
| 3980- | Lut, | Zeax, | Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease |
| - | Trial, | AD, | NA |
| 3982- | Lut, | Zeax, | Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined |
| - | Trial, | AD, | NA |
| 3261- | Lyco, | Lycopene and Vascular Health |
| - | Review, | Stroke, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:961 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid